Physician profile
Crystal Y Colone
NPI 1265742514
$17,237.78
in general payments reported to CMS, 2019-2025
27 companies · $4,283 in 2025
The $4,283 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,837 · 2022: $2,863 · 2023: $4,018 · 2024: $4,237 · 2025: $4,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,537.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,033.96 | 2021-2025 | Invega Trinza, Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,881.45 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,843.25 | 2021-2025 | |
| Alkermes, INC. | $1,791.26 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,728.38 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $1,575.11 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,245.81 | 2022-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $1,164.08 | 2021-2025 | Ingrezza |
| Novo Nordisk INC | $835.51 | 2021-2025 | Wegovy, Saxenda |
| Lundbeck LLC | $659.76 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $643.81 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $506.20 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $280.83 | 2021-2022 | |
| Axsome Therapeutics, INC. | $243.51 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $178.10 | 2021-2024 | Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $171.68 | 2021-2022 | |
| Almatica Pharma LLC | $104.71 | 2024-2025 | Loreev Xr |
| Owp Pharmaceuticals, INC. | $62.85 | 2024 | Subvenite |
| Lilly USA, LLC | $59.14 | 2023-2025 | Zepbound, Jardiance |
| Luye Pharma (USA) LTD. | $48.37 | 2025 | Erzofri Extended-Release |
| Adlon Therapeutics L.P. | $38.90 | 2021 | |
| Sun Pharmaceutical Industries INC. | $36.63 | 2021 | |
| Eisai INC. | $33.00 | 2021-2022 | |
| Noven Therapeutics, LLC | $19.85 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.08 | 2024 | Quviviq |
| Tris Pharma INC | $13.90 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Colone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.